A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT06378177 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL: LVGN6051 Monoclonal Antibody Injection
BIOLOGICAL: toripalimab Injection
DRUG: Paclitaxel injection

Sponsor

Lyvgen Biopharma Holdings Limited